Advertisement
Concise CommunicationIn-Press PreviewGeneticsNeuroscience Free access | 10.1172/JCI142574
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by
Schmid, R.
in:
JCI
|
PubMed
|
Google Scholar
|
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by Deng, X. in: JCI | PubMed | Google Scholar
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by
Panikker, P.
in:
JCI
|
PubMed
|
Google Scholar
|
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by Msackyi, M. in: JCI | PubMed | Google Scholar
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by Breton, C. in: JCI | PubMed | Google Scholar
1Gene Therapy Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
Find articles by Wilson, J. in: JCI | PubMed | Google Scholar
Published January 7, 2021 - More info
Gene editing holds the potential to correct mutations and cure devastating genetic disorders. The technology has not yet proven efficacious for therapeutic use in central nervous system (CNS) diseases with ubiquitous neuronal defects. Angelman syndrome (AS), a severe neurodevelopmental disorder, is caused by a lack of maternal expression of the UBE3A gene. Due to genomic imprinting, only neurons are affected. One therapeutic approach focuses on the intact paternal UBE3A copy in AS patients that is silenced by an antisense transcript (UBE3A-ATS). We show here that gene editing of Ube3a-ATS in the mouse brain results in the formation of base pair insertions/deletions (indels) in neurons and the subsequent unsilencing of the paternal Ube3a allele in neurons, which partially corrects the behavior phenotype of a murine AS model. This study provides compelling evidence to further investigate editing of the homologous region of the human UBE3A-ATS, since this may provide a lasting therapeutic effect for AS patients.